Entera Bio Ltd. (ENTX)
NASDAQ: ENTX · Real-Time Price · USD
2.220
+0.080 (3.74%)
At close: Oct 24, 2025, 4:00 PM EDT
2.180
-0.040 (-1.80%)
After-hours: Oct 24, 2025, 4:22 PM EDT
Entera Bio Revenue
Entera Bio had revenue of $166.00K in the twelve months ending June 30, 2025, up 191.23% year-over-year. In the year 2024, Entera Bio had annual revenue of $181.00K.
Revenue (ttm)
$166.00K
Revenue Growth
+191.23%
P/S Ratio
613.43
Revenue / Employee
$8,300
Employees
20
Market Cap
102.51M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 181.00K | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | 134.00K | -437.00K | -76.53% |
| Dec 31, 2021 | 571.00K | 206.00K | 56.44% |
| Dec 31, 2020 | 365.00K | 129.00K | 54.66% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
ENTX News
- 1 day ago - Entera Bio Presents Positive New Clinical Data from EB613 Phase 2 Trial Demonstrating Significant Bone Density Improvements in Early Postmenopausal Women - GlobeNewsWire
- 8 days ago - Entera Bio to Present New Clinical Data from Phase 2 Trial of EB613 at the 2025 North American Menopause Society (NAMS) Annual Meeting - GlobeNewsWire
- 2 months ago - Entera Bio Announces Second Quarter 2025 Financial Results and Business Updates - GlobeNewsWire
- 3 months ago - Entera Bio Receives FDA Agreement on BMD as Primary Endpoint for EB613 Registrational, Phase 3 Study in Post-Menopausal Women with Osteoporosis - GlobeNewsWire
- 6 months ago - Entera Bio Announces First Quarter 2025 Financial Results and Business Updates - GlobeNewsWire
- 7 months ago - Entera Bio Announces Full Year 2024 Financial Results and Provides Business Updates - GlobeNewsWire
- 7 months ago - OPKO Health and Entera Bio Enter into Collaboration Agreement to Advance Oral GLP-1/Glucagon Tablet Candidate into the Clinic to Treat Obesity and Metabolic Disorders - GlobeNewsWire
- 8 months ago - Entera Bio to Participate in Upcoming Events - GlobeNewsWire